LONGEVA.

Nicotinamide riboside (NR): adverse events and evidence limits

In four-week NR-SAFE, oral NR chloride in Parkinson’s disease was accompanied by mild headache, nausea and dyspepsia; causal attribution varied. [1]

In a retrospective series of eight adults receiving IV NR over four days, tingling and cramps occurred. One infusion paused for menstrual-associated cramping, described inconsistently as severe/mild. These compounded-product observations do not establish oral NR risks. [2]

What the studies reported

EffectModel or participantsHow often or as describedSource
HeadachePatients with Parkinson’s disease, oral NR chloride, four-week NR-SAFE trialObserved, mild; causal attribution varied; no percentage given[1]
NauseaThe same patientsObserved, mild; no frequency given[1]
DyspepsiaThe same patientsObserved, mild; no frequency given[1]
TinglingEight adults, intravenous NR over four days (retrospective series)Occurred; these observations do not establish oral NR risks[2]
CrampsThe same adultsOccurred; one infusion paused for menstrual-associated cramping, described inconsistently as severe/mild[2]

References

  1. Haakon Berven et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease https://doi.org/10.1038/s41467-023-43514-6.
  2. Kirsten Reyna et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting https://doi.org/10.3389/fragi.2026.1652582.